The AHEAD Study aims to help prevent Alzheimer’s disease, funded by the National Institutes of Health (NIH) and Eisai Inc., by testing an investigational treatment aimed at delaying memory loss before noticeable signs of Alzheimer’s disease begin.
The AHEAD Study is an innovative clinical trial aiming to get ahead of the disease before symptoms are noticeable. Lecanemab is an FDA-approved medication for mild cognitive impairment and mild dementia due to Alzheimer’s disease. The AHEAD Study tests whether starting this treatment in people with amyloid plaques (a toxic protein in the brain) before symptoms start can help prevent memory loss altogether. Mayo Clinic is one of 75 research locations across the United States and Canada conducting the AHEAD Study.
The study is the first of its kind to:
- Enroll participants as young as 55 years old who are at risk of developing symptoms of Alzheimer’s disease as they get older;
- Use a blood test to rule out people not likely to be eligible based on amyloid PET imaging;
- Target the earliest changes in the brain due to Alzheimer’s disease by enrolling participants with intermediate levels of brain amyloid;
- Use an approach that tailors dose levels of the investigational treatment to study participants’ brain amyloid levels;
- Test an investigational treatment that has been shown to lower brain amyloid in people with symptoms of Alzheimer’s.